Venlafaxine: uses, dosing, side effects & brands

Effexor XR is an extended-release capsule for once-a-day oral administration that contains venlafaxine hydrochloride, a serotonin and norepinephrine reuptake inhibitor (SNRI).

The FDA classifies venlafaxine as a serotonin and norepinephrine reuptake inhibitor. SNRIs slow the reabsorption of two brain chemicals, serotonin and norepinephrine, back into nerve cells. This leaves more of both available in the gaps between neurons to keep signaling, which can improve mood, anxiety, and certain types of chronic pain. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The label (Pregnancy Category C) states there are no adequate and well-controlled studies in pregnant women, and that venlafaxine should be used during pregnancy only if clearly needed. Animal studies showed no malformations but did show decreased pup weight, more stillborn pups, and increased early pup deaths at high doses. It warns that neonates exposed late in the third trimester to venlafaxine, other SNRIs, or SSRIs have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (e.g., respiratory distress, apnea, seizures, temperature instability, feeding difficulty, jitteriness, irritability) — consistent with either drug toxicity or a discontinuation syndrome. When treating during the third trimester, the label says the physician should carefully weigh risks and benefits. It advises patients to notify their physician if they become or intend to become pregnant. Discuss any decision with your prescriber; do not start or stop on your own. This is what venlafaxine's FDA label says; whether to use it in pregnancy is your prescriber's decision.

The label reports a dose-dependent weight loss in adults treated with venlafaxine over several weeks, and lists weight loss as an adverse reaction (about 1% in trials, versus none on placebo). More patients on the extended-release form than on placebo had a weight loss of at least 3.5% in both the MDD and GAD studies (18% of venlafaxine-treated patients). Discontinuation due to weight loss was uncommon (0.1%). The label notes venlafaxine is not indicated for weight loss and should not be combined with weight-loss agents. In children and adolescents it warns of increases in weight less than expected for age- and sex-matched peers. Weight gain appears only as an infrequent event in a broad post-marketing adverse-reaction list, not as a systematic finding.

The label addresses alcohol directly. Under Information for Patients it states that although venlafaxine has not been shown to increase the mental and motor impairment caused by alcohol, patients should be advised to avoid alcohol while taking it; the Medication Guide likewise says do not drink alcohol while using venlafaxine. This is a precautionary avoid instruction, not a disulfiram-like reaction. Separately, a pharmacokinetic study cited under Drug Interactions found a single dose of ethanol had no effect on venlafaxine levels and venlafaxine did not exaggerate alcohol's psychomotor effects. This is what venlafaxine's FDA label says; alcohol advice depends on your dose and health, so confirm with your pharmacist.

The label describes a discontinuation syndrome. Abrupt discontinuation or dose reduction of venlafaxine has been associated with new symptoms whose frequency rises with higher dose and longer treatment. Reported symptoms include agitation, anxiety, confusion, dizziness, dysphoric mood, insomnia, nervousness, nightmares, headache, nausea, sweating, tremor, fatigue, flu-like symptoms, and sensory disturbances including shock-like electrical sensations. The label directs that discontinuation be managed by the prescriber with a gradual reduction in dose rather than abrupt cessation whenever possible, and that if intolerable symptoms occur the prior dose may be resumed and then tapered more slowly. This withdrawal guidance is not part of the boxed warning (the boxed warning concerns suicidality). Do not stop venlafaxine on your own — any change is a prescriber-managed decision.

The elimination half-life of venlafaxine is about 5 hours (mean roughly 5 ± 2 hours) for the parent drug venlafaxine in adults with normal organ function — that is how long the body takes to clear half of a dose. Venlafaxine's major active metabolite, O-desmethylvenlafaxine (ODV), has a materially longer elimination half-life of about 11 hours (11 ± 2 hours), so the drug's overall duration of effect is longer than the parent value alone suggests; the label also notes both are cleared more slowly (half-life prolonged) in people with hepatic or renal impairment. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run venlafaxine against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 3 venlafaxine-containing products in the U.S.: Effexor, Effexor XR and Venlafaxine Hydrochloride. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, venlafaxine is currently marketed as tablet, capsule, extended release and tablet, extended release, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 1 generic venlafaxine product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

The FDA's Enforcement database lists 4 recall records whose product description mentions venlafaxine. The most recent: Venlafaxine Tablets (Mar 21, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

It works gradually, not overnight. You may notice some early changes — sleep, appetite or energy — within the first 1 to 2 weeks, but the full effect on mood or anxiety usually takes about 4 to 6 weeks (sometimes up to 8). That delay is normal and is why prescribers ask you not to judge it too soon or stop early; give it time and stay in touch about side effects, and never stop abruptly.

Alcohol: the FDA label says to avoid alcohol — see the alcohol section above for what it actually says. This is what the FDA label and our cited sources say — it is not a complete list. Your pharmacist can check your own combination.

The most frequently reported side effects of Effexor (venlafaxine), an SNRI antidepressant, are nausea, headache, dry mouth, sweating, and either drowsiness or insomnia. MedlinePlus also lists loss of appetite, dizziness, and sexual side effects (decreased sex drive, delayed or absent orgasm, and erectile or ejaculation problems). Nausea is often worst in the first week or two and usually eases as your body adjusts; taking the dose with food can help. These are general effects, not a complete list.

Get emergency help for signs of serotonin syndrome, which the FDA label calls "a potentially life-threatening condition" and MedlinePlus describes as "fever, sweating, confusion, fast or irregular heartbeat, severe muscle stiffness or twitching," plus agitation or hallucinations — the risk is higher when venlafaxine is combined with other serotonergic drugs (including triptans, tramadol, or MAOIs). Also seek urgent care for a seizure, "fast, pounding, or irregular heartbeat," chest pain or trouble breathing, or an allergic reaction ("rash; hives; itching; difficulty breathing or swallowing"). Low sodium (hyponatremia) can cause headache, weakness, confusion, or unsteadiness and needs prompt medical attention. This is not a complete list of serious effects.

Yes. Effexor (venlafaxine) carries the FDA's boxed warning shared by all antidepressants: "Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients" — that is, in people under 25, especially in the first months of treatment and after any dose change. MedlinePlus says to watch for new or worsening depression, suicidal thoughts, agitation, panic attacks, severe restlessness, aggression, or unusual excitement, and to contact the prescriber right away if these appear. The warning does not mean the drug is unsafe for everyone; it means close monitoring matters early on.

Both are documented, dose-related concerns. Venlafaxine can cause elevated blood pressure, and the FDA label advises to "Monitor blood pressure before initiating treatment and regularly during treatment" and to "Control pre-existing hypertension before initiating" it — higher doses carry more risk. It can also increase bleeding: the label notes drugs affecting serotonin reuptake "may increase the risk of bleeding events, ranging from ecchymoses, hematomas, epistaxis, petechiae, and gastrointestinal hemorrhage to life-threatening hemorrhage," particularly when combined with NSAIDs (ibuprofen, aspirin) or blood thinners. Tell your prescriber about any unusual bruising or bleeding.

Venlafaxine has one of the harshest antidepressant discontinuation syndromes, partly because of its short half-life. The FDA label states that "Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms," such as agitation, anxiety, dizziness, nausea, tremor, and sweating, and MedlinePlus warns: "Do not stop taking venlafaxine without talking to your doctor." People commonly report "brain zaps" (electric-shock sensations), flu-like feelings, and mood swings when doses are missed or stopped. The label recommends "a gradual reduction in dose" — never stop on your own; work out a taper schedule with your prescriber.

Physical side effects like nausea, headache, and dizziness usually appear within the first days and often settle over one to two weeks as your body adapts. Full antidepressant benefit typically takes several weeks, so side effects can precede the mood improvement. Sexual side effects and sweating may persist as long as you take the drug. Because withdrawal can be difficult, any decision to stop should be a planned, gradual taper with your prescriber rather than an abrupt halt. If side effects are severe or don't improve, contact your prescriber rather than adjusting the dose yourself.